Overview
Vymada Tablets contain a combination of Sacubitril and Valsartan, indicated for the treatment of heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, increasing protective peptides, while Valsartan blocks angiotensin II receptors, relaxing blood vessels and reducing cardiac workload.





